JP7657548B2 - 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 - Google Patents

獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 Download PDF

Info

Publication number
JP7657548B2
JP7657548B2 JP2019556941A JP2019556941A JP7657548B2 JP 7657548 B2 JP7657548 B2 JP 7657548B2 JP 2019556941 A JP2019556941 A JP 2019556941A JP 2019556941 A JP2019556941 A JP 2019556941A JP 7657548 B2 JP7657548 B2 JP 7657548B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
il13r
il4r
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517262A (ja
JP2020517262A5 (enExample
Inventor
ハンチュン チャン，
ラム グエン，
フォーン チエン，
シー ジアン リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elanco US Inc
Original Assignee
Elanco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco US Inc filed Critical Elanco US Inc
Publication of JP2020517262A publication Critical patent/JP2020517262A/ja
Publication of JP2020517262A5 publication Critical patent/JP2020517262A5/ja
Priority to JP2023028068A priority Critical patent/JP7776461B2/ja
Application granted granted Critical
Publication of JP7657548B2 publication Critical patent/JP7657548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019556941A 2017-04-21 2018-04-20 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 Active JP7657548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023028068A JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488509P 2017-04-21 2017-04-21
US62/488,509 2017-04-21
PCT/US2018/028507 WO2018195388A1 (en) 2017-04-21 2018-04-20 Il4/il13 receptor molecule for veterinary use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023028068A Division JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Publications (3)

Publication Number Publication Date
JP2020517262A JP2020517262A (ja) 2020-06-18
JP2020517262A5 JP2020517262A5 (enExample) 2021-05-27
JP7657548B2 true JP7657548B2 (ja) 2025-04-07

Family

ID=63856393

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556941A Active JP7657548B2 (ja) 2017-04-21 2018-04-20 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
JP2023028068A Active JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023028068A Active JP7776461B2 (ja) 2017-04-21 2023-02-27 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子

Country Status (10)

Country Link
US (2) US11970526B2 (enExample)
EP (1) EP3612555A4 (enExample)
JP (2) JP7657548B2 (enExample)
KR (2) KR20200006528A (enExample)
CN (1) CN110770250B (enExample)
AU (2) AU2018254542B2 (enExample)
BR (1) BR112019021812A2 (enExample)
CA (1) CA3059731A1 (enExample)
MX (1) MX2019012570A (enExample)
WO (1) WO2018195388A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JP7657548B2 (ja) 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
AU2018318440A1 (en) * 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
EP3870601A4 (en) * 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
JP7671275B2 (ja) 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
MX2022013149A (es) * 2020-04-22 2023-02-09 Kindred Biosciences Inc Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
WO2021249555A1 (en) * 2020-06-12 2021-12-16 Beijing Vdjbio Co., Ltd. Fusion polypeptide
US20240368249A1 (en) 2021-08-20 2024-11-07 Intervet Inc. Fusion proteins for treating atopic dermatitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161724A (ja) 2003-12-23 2007-06-28 Tanox Inc 新規抗ｉｌ１３抗体およびその使用
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6743604B1 (en) * 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7507706B1 (en) * 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2005032399A2 (en) 2003-05-30 2005-04-14 The Regents Of The University Of California Il4 receptor antagonists for horse, dog and cat
CN1922204A (zh) * 2004-02-27 2007-02-28 瑞泽恩制药公司 Il－4/il－13特异性的多肽和其治疗应用
US8354109B2 (en) 2005-12-13 2013-01-15 Suppremol Gmbh Multimeric Fc receptor polypeptides
EP2674440B1 (en) * 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CA2672215A1 (en) * 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
US20090156421A1 (en) * 2007-11-06 2009-06-18 Wyeth Assays and methods for evaluating multimeric complexes
EP2220125A4 (en) 2007-11-13 2010-12-29 Sapphire Energy Inc PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
WO2012149439A2 (en) * 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
EP3453400B1 (en) 2011-12-13 2021-01-20 Pieris Pharmaceuticals GmbH Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
KR102502640B1 (ko) * 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP3954710A3 (en) 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CN108135850A (zh) * 2015-07-29 2018-06-08 纳米提克斯有限责任公司 用于清除可溶性生物分子的模块化组合物及其相关方法
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
JP7657548B2 (ja) 2017-04-21 2025-04-07 エランコ・ユーエス・インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
EP3870601A4 (en) 2018-10-25 2022-07-13 Kindred Biosciences, Inc. IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE
MX2022013149A (es) 2020-04-22 2023-02-09 Kindred Biosciences Inc Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161724A (ja) 2003-12-23 2007-06-28 Tanox Inc 新規抗ｉｌ１３抗体およびその使用
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
" Full=Uncharacterized protein {ECO:0000313|Ensembl:ENSCAFP00000030717};GNName=IL13RA1 {ECO:0000313, 2017年03月15日, 掲載日, https://www.uniprot.org/uniprot/E2QZ78.txt?version=38
" Full=Uncharacterizedprotein {ECO:0000313|Ensembl:ENSCAFP00000025718};GN Name=IL4R {ECO:0000313|En, 2017年03月15日, 発行日, https://www.uniprot.org/uniprot/E2RFN6.txt?version=43

Also Published As

Publication number Publication date
CA3059731A1 (en) 2018-10-25
US20200048325A1 (en) 2020-02-13
NZ757956A (en) 2026-02-27
JP2020517262A (ja) 2020-06-18
AU2018254542B2 (en) 2022-12-22
WO2018195388A1 (en) 2018-10-25
RU2019137211A (ru) 2021-05-21
JP2023078158A (ja) 2023-06-06
CN110770250A (zh) 2020-02-07
JP7776461B2 (ja) 2025-11-26
US20240270820A1 (en) 2024-08-15
KR20250057131A (ko) 2025-04-28
AU2023201726B2 (en) 2024-11-21
AU2023201726A1 (en) 2023-04-27
AU2018254542A1 (en) 2019-11-21
RU2019137211A3 (enExample) 2021-09-09
BR112019021812A2 (pt) 2020-05-26
CN110770250B (zh) 2025-01-07
EP3612555A4 (en) 2020-12-30
EP3612555A1 (en) 2020-02-26
MX2019012570A (es) 2019-12-02
US11970526B2 (en) 2024-04-30
KR20200006528A (ko) 2020-01-20

Similar Documents

Publication Publication Date Title
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US12428466B2 (en) IL4/IL13 receptor molecule for veterinary use
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
US20220169740A1 (en) NGF Antagonists for Medical Use
KR20200057701A (ko) 수의과용 igg fc 변이체
JP7671275B2 (ja) 動物用の抗ｉｌ３１抗体
US12583917B2 (en) IL17A antibodies and antagonists for veterinary use
CN107683291A (zh) 针对犬白介素‑4受体α的抗体
JP2023506923A (ja) イヌインターロイキン－４受容体α抗体
RU2795591C2 (ru) Молекула рецептора il4/il13 для ветеринарного применения
RU2829812C2 (ru) Антагонисты ngf для медицинского использования

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230227

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230425

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230602

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250326

R150 Certificate of patent or registration of utility model

Ref document number: 7657548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150